Immusoft raises $20M Series B to advance ISP gene therapy and push ISP-001 into Phase I/II for MPS I
Seattle biotech Immusoft raised $20 million in a Series B round to advance its immune system programming (ISP) gene therapy platform, aiming to move lead candidate ISP-001 into Phase I/II trials for MPS I and generate initial safety and efficacy data in 2019; ISP uses patients' blood cells modified to secrete therapeutic proteins and has FDA orphan and rare pediatric disease designations. The company credits progress under new CEO Sean Ainsworth, who replaced founder Matthew Scholz as CEO last year (Scholz is now CTO), and says the platform could broadly replace recombinant enzyme replacement therapies.